News

Envista (NVST) reported $623.6 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 0.6%. EPS of $0.26 for the same period compares to $0.38 a year ago.

The reported revenue represents a surprise of -0.87% over the Zacks Consensus Estimate of $629.06 million. With the consensus EPS estimate being $0.31, the EPS surprise was -16.13%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Envista performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Sales- North America: $318.70 million versus the three-analyst average estimate of $331.95 million. The reported number represents a year-over-year change of -1.9%.
• Geographic Sales- Western Europe: $148.30 million compared to the $151.67 million average estimate based on three analysts. The reported number represents a change of -0.5% year over year.
• Geographic Sales- Emerging markets: $126.30 million versus the three-analyst average estimate of $112.94 million.
• Geographic Sales- Other developed markets: $30.30 million compared to the $33.10 million average estimate based on three analysts. The reported number represents a change of -7.1% year over year.
• Geographic Sales- Specialty Products & Technologies- North America: $171.10 million versus the three-analyst average estimate of $184.73 million. The reported number represents a year-over-year change of -7.7%.
• Geographic Sales- Equipment & Consumables- Emerging markets: $33.10 million versus the three-analyst average estimate of $28.14 million.
• Geographic Sales- Specialty Products & Technologies- Other developed markets: $22.10 million versus the three-analyst average estimate of $24.57 million. The reported number represents a year-over-year change of -7.9%.
• Geographic Sales- Specialty Products & Technologies- Emerging markets: $93.20 million versus the three-analyst average estimate of $84.80 million.
• Geographic Sales- Equipment & Consumables- North America: $147.60 million versus the three-analyst average estimate of $147.22 million. The reported number represents a year-over-year change of +5.9%.
• Geographic Sales- Equipment & Consumables- Western Europe: $26 million versus the three-analyst average estimate of $31.90 million. The reported number represents a year-over-year change of -19%.
• Sales- Equipment & Consumables: $214.90 million versus the four-analyst average estimate of $212.49 million. The reported number represents a year-over-year change of -1.1%.
• Sales- Specialty Products & Technologies: $408.70 million versus the four-analyst average estimate of $419.35 million. The reported number represents a year-over-year change of -0.3%.

View all Key Company Metrics for Envista here>>>

Shares of Envista have returned -3.2% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

5 Stocks Set to Double

Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.